Background: Chronic HIV-infection is associated with damage of the intestinal epithelium partly by disrupting the Th17/Treg balance and contributing to systemic immune activation, a marker for disease progression. The initiation of anti-retroviral treatment (ART) early during acute HIV-infection (AHI) might represent an opportunity to intervene and limit destruction of the mucosal barrier. Methodology: 38 subjects in Fiebig stages I to III were enrolled and underwent sigmoid biopsy at baseline, 6 months (29/38) and 24 months (17/38) post initiation of ART. Ten gender- and age-matched HIV uninfected (HIV-) and 5 ART-naive chronically HIV+ subjects (CHI), 6 to 12 month post infection, served as controls. Mucosal mononuclear cells were isolated and subsequently stained for multi-parameter flow cytometry. Results: At baseline, subjects were Fiebig stage: I (13), II (4) and III (21). A significantly lower frequency of Th17 cells was observed in FIII compared to FI/ II (Median 7.1% vs. 13.2%, p=0.03). No difference was seen between FI/II and HIV- (Median 13.2% vs. 14.5%, p=NS), while FIII had lower Th17 cells compared to HIV- (Median 7.1% vs. 14.3%, p=0.01). Subjects who started ART in FI/II maintained frequencies of Th17 cells at 6 months (Median 13.5%) and 24 months (Median 12.7%) comparable to HIV-, while Th17 cells were depleted in (CHI) (Median 1.1%, p<0.001). Initiation of ART at FIII prevented further loss of Th17 cells, but did not reconstitute Th17 frequencies to the level of HIV- (Median baseline: 7.1%, 6 months: 9.2%, 24 months: 8.1%, HIV- 14.5%). At 24 months subjects treated at FI/II and at FIII maintained higher frequencies of Treg compared to HIV- (Median FI/II 6.7%, p=0.001 and FIII 7.7%; p=0.003 vs. HIV- 3.1%), but never increased to levels seen in CHI (Median 20.6%). Additionally, FIII subjects showed significantly increased CD8 T cell activation before ART compared to HIV- as measured by HLA-DR/CD38 expression (Median 12.7% vs. 4.7%, p<0.001). However, at 6 and 24 months CD8 T cell activation decreased to frequencies similar to HIV- with 4.5% and 5.1%, respectively. FI/II subjects did not show an initial significant increase in CD8 T cell activation compared to HIV- (Median 6.9% vs. 4.7%, p=NS) and maintained low levels of immune activation at 6 and 24 months (Median 5.5% and 4.9%). Conclusions: FI/II subjects exhibit levels of Th17 cells and CD8 T cell activation similar to HIV- subjects and maintain those levels under ART. Early initiation of ART may prevent the loss of Th17 cells and subsequent CD8 T cell activation thus contributing to the integrity of the mucosal barrier.